Prostate cancer imaging showdown: which drug hits tumors harder?
Knowledge-focused
Terminated
This early-stage study compared two radioactive drugs (177Lu rhPSMA-10.1 and 177Lu vipivotide tetraxetan, also known as Pluvicto) in 17 men with metastatic prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors while sparing the kid…
Phase: EARLY_PHASE1 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC